[CAS NO. 299-27-4] D-Gluconic acid potassium
PRODUCTS SPECIFICATIONS [299-27-4]
DESCRIPTION [299-27-4]
Overview
| MDL | MFCD00064211 |
|---|---|
| Molecular Weight | 234.25 |
| Molecular Formula | C6H11KO7 |
| SMILES | O[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)C(O[K])=O |
Summary
Potassium Gluconate (Potassium D-gluconate) is an orally active carboxylic acid by the oxidation with antiseptic and chelating properties [1] .
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
Potassium Gluconate, a simple sugar acid, is the most significant antifungal metabolite produced by Pseudomonas . str. AN5 against the take-all fungal pathogen in biocontrol protection [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02399449 | University of Maryland, Baltimore |
Anemia
|
September 15, 2017 | Phase 4 |
| NCT04063033 | Rambam Health Care Campus |
Heart Failure
|
September 1, 2019 | Phase 4 |
| NCT00224042 | Watson Pharmaceuticals |
Anemia, Iron-Deficiency|Kidney Failure, Chronic
|
April 2003 | Phase 4 |
| NCT00534144 | Watson Pharmaceuticals |
Kidney Failure, Chronic|Anemia, Iron-Deficiency
|
September 2007 | Phase 1 |
| NCT00224003 | Watson Pharmaceuticals |
Anemia
|
April 2003 | Phase 4 |
| NCT01925703 | University of North Carolina, Chapel Hill |
Heart Failure|Iron Deficiency Anemia
|
April 2011 | Phase 4 |
| NCT00224055 | Watson Pharmaceuticals |
Anemia, Iron-Deficiency|Kidney Failure, Chronic
|
April 2003 | Phase 4 |
| NCT00661999 | Mayo Clinic|National Cancer Institute (NCI) |
Anemia|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific
|
January 2006 | Phase 3 |
| NCT00354692 | Watson Pharmaceuticals |
Kidney Failure, Chronic|Anemia, Iron-Deficiency
|
June 2006 | Phase 4 |
| NCT03563573 | AlkaliDx, Inc. |
ADHD
|
July 1, 2018 | Phase 1|Phase 2 |
| NCT02697708 | Purdue University|Alliance for Potato Research and Education |
Hypertensive Disease
|
April 27, 2016 | Phase 1|Phase 2 |
| NCT00223938 | Sanofi |
Anemia
|
December 30, 2003 | Phase 4 |
| NCT00223977 | Watson Pharmaceuticals |
Iron Deficiency Anemia
|
December 2003 | Phase 2|Phase 3 |
| NCT04797832 | Rambam Health Care Campus |
Iron Deficiency Anemia Due to Blood Loss|Aortic Stenosis
|
October 18, 2020 | Phase 4 |
| NCT01881295 | Purdue University|Alliance for Potato Research and Education |
Potassium Bioavailability|Blood Pressure
|
March 1, 2013 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL ( 426.89 mM ; Need ultrasonic)
DMSO : 1.25 mg/mL ( 5.34 mM ; ultrasonic and warming and heat to 80°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.2689 mL | 21.3447 mL | 42.6894 mL |
| 5 mM | 0.8538 mL | 4.2689 mL | 8.5379 mL |
| 10 mM | 0.4269 mL | 2.1345 mL | 4.2689 mL |
Synonyms